pre-IPO PHARMA

COMPANY OVERVIEW

Twentyeight-Seven Therapeutics is a biotechnology company focused on the modulation of RNA to treat cancer and other human diseases. Targeting RNA modulating proteins (RMPs), the company can use small molecules to control the expression levels of oncogenes and other proteins of significance. The company’s core technology comes from its four founding scientists, all leading researchers in RNA biology and cancer.


LOCATION

  • Watertown, MA, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://twentyeight-seven.com


    CAREER WEBSITE

    https://www.twentyeight-seven.com/careers/


    SOCIAL MEDIA


    INVESTORS

    astellas-venture-management mpm-capital novartis-venture-fund vertex-ventures-hc


    PRESS RELEASES


    Nov 2, 2022

    Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics


    May 9, 2019

    Sofinnova Partners Invests in Twentyeight-Seven Therapeutics


    Sep 6, 2018

    Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding


    For More Press Releases


    Google Analytics Alternative